Pelthos Therapeutics Inc. (NYSE MKT:PTHS) — Market Cap & Net Worth
Market Cap & Net Worth: Pelthos Therapeutics Inc. (PTHS)
Pelthos Therapeutics Inc. (NYSE MKT:PTHS) has a market capitalization of $85.55 Million ($85.55 Million) as of August 27, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #19897 globally and #4514 in its home market, demonstrating a -3.72% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pelthos Therapeutics Inc.'s stock price $26.66 by its total outstanding shares 3355543 (3.36 Million). Check Pelthos Therapeutics Inc. (PTHS) share price today for real-time trading data and today's change.
Pelthos Therapeutics Inc. Market Cap History: 2025 to 2026
Pelthos Therapeutics Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $104.02 Million to $89.46 Million (0.00% CAGR).
Pelthos Therapeutics Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pelthos Therapeutics Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Pelthos Therapeutics Inc. (PTHS) net assets to evaluate the company's book value and shareholders' equity.
Latest Price to Sales (P/S) Ratio
6.19x
Pelthos Therapeutics Inc.'s market cap is 6.19 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $104.02 Million | $16.80 Million | -$43.32 Million | 6.19x | N/A |
Competitor Companies of PTHS by Market Capitalization
Companies near Pelthos Therapeutics Inc. in the global market cap rankings as of August 27, 2026. Also see PTHS cash flow conversion for how efficiently the company converts equity into cash flow.
Key companies related to Pelthos Therapeutics Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #191 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #329 globally with a market cap of $82.41 Billion USD.
- CSL Ltd (AU:CSL): Ranked #466 globally with a market cap of $59.19 Billion USD ( AU$83.66 Billion AUD).
- Samsung Biologics Co Ltd (KO:207940): Ranked #552 globally with a market cap of $50.16 Billion USD ( ₩74.02 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #191 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.29 |
| #329 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $82.41 Billion | $814.79 |
| #466 | CSL Ltd | AU:CSL | $59.19 Billion | AU$172.44 |
| #552 | Samsung Biologics Co Ltd | KO:207940 | $50.16 Billion | ₩1599000.00 |
Pelthos Therapeutics Inc. Historical Marketcap From 2025 to 2026
Between 2025 and today, Pelthos Therapeutics Inc.'s market cap moved from $104.02 Million to $ 89.46 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $89.46 Million | -14.00% |
| 2025 | $104.02 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 27th, 2026 the market cap of Pelthos Therapeutics Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $85.55 Million USD |
| MoneyControl | $85.55 Million USD |
| MarketWatch | $85.55 Million USD |
| marketcap.company | $85.55 Million USD |
| Reuters | $85.55 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus… Read more